AI-generated summary
The authors studied 248 patients aged 38 to 65 with rheumatoid arthritis and secondary osteoarthritis, comparing four treatment groups over 6 months. They report statistically significant functional improvements and lower disease activity in groups receiving an interleukin-1 inhibitor, along with changes in serum IL-1 and COMP levels. The abstract does not describe comparison of outcomes across all groups in detail.
- Participants
- 248
- Who or what was studied
- Patients aged 38 to 65 with rheumatoid arthritis and secondary osteoarthritis, mostly Stage II by DAS28
- Limits stated in the abstract
- The abstract does not describe randomization, blinding, or a control group design, and reports only 6-month outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on mediasphera.ru.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Osteoarthritis, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.